New drug aims to boost Cancer-Fighting CAR-T cells in tough myeloma cases
NCT ID NCT07200089
Summary
This early-stage study is testing whether adding an experimental drug called NT-I7 to standard CAR-T cell therapy helps control multiple myeloma for longer. The research will involve 40 adults with myeloma that has returned or stopped responding to other treatments. Participants will receive their planned CAR-T therapy and be randomly assigned to also get either NT-I7 or a placebo injection to compare safety and see if NT-I7 helps the CAR-T cells work better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.